What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

December 8, 2025BloodOpen Access

Anti-CD7 CAR T-cell therapy for ultra-high-risk relapsed/refractory T-ALL/lbl: Insights into lineage switch and consolidation strategies

View Full Paper

Ask AI

Bookmark

Authors

Phase I trial shows high overall response rates with CD7 CAR T-cell therapy in T-cell lymphoblastic lymphoma, suggesting benefits of allo-SCT.

Complete remission was achieved in 100% for bone marrow disease, while overall response rates reached 78.5% for extramedullary lymphoma.
Overall survival at six months was 70.7%, highlighting the efficacy of CD7 CAR T-cell therapy in aggressive cases of T-cell lymphoblastic lymphoma.
Allogeneic stem cell transplantation significantly improved outcomes, with a six-month OS of 100% for this subgroup.
Monitoring for cytokine release syndrome is essential, with notable toxicity profiles observed during treatment.

Song et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase I trial shows high overall response rates with CD7 CAR T-cell therapy in T-cell lymphoblastic lymphoma, suggesting benefits of allo-SCT.

Complete remission was achieved in 100% for bone marrow disease, while overall response rates reached 78.5% for extramedullary lymphoma.
Overall survival at six months was 70.7%, highlighting the efficacy of CD7 CAR T-cell therapy in aggressive cases of T-cell lymphoblastic lymphoma.
Allogeneic stem cell transplantation significantly improved outcomes, with a six-month OS of 100% for this subgroup.
Monitoring for cytokine release syndrome is essential, with notable toxicity profiles observed during treatment.

Song et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark